Yarrow Bioscience, Inc.

YARW
About the company

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure.

Country: United StatesPrice: $18.03Market Cap: $206.9M

Investment snapshot

29%positive consensus
Scored 1d ago

Positive

5

BUY / PASS

Neutral / negative

2 / 9

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Strongest signal

10 of 12 pass — Buffett and Marks object

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2794 (Top 90.2%)PASSFAILPASSFAILFAILFAILPASSPASSPASSNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

Annual history · FY 2025 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-27

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-27

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-27

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-02-27

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · Balance sheet at 2026-06-30

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-02-27

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-02-27

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-27

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-02-27

Score computed: 2026-11-14

Where It Passes

  • Debt & Leverage83% pass✓ 13✗ 2▾

    10 of 12 pass — Buffett and Marks object

    LT Debt vs Net Current AssetsLT Debt $0.0M vs NCA $22.0M
    ✓GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: 0.00, IC: N/A
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity0
    ✓Lynch< 0.33
    Cash - Long-term Debt$22.9M
    ✓LynchPositive preferred
    LT Debt / Total Assets Change0.00% -> 0.00%
    ✓PiotroskiDecreased YoY
    Current Assets / Current Liabilities15.26
    ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity0
    ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
    Debt Levels0
    ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDA
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity0
    ✓Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-0.0000; #1/4210 (top 0.0%)
    ✓AsnessTop 30% of eligible cross-section

Where It Falls Short

  • Valuation0% pass✓ 1✗ 27▾

    No clean pass — all 13 investors flag at least one valuation criterion

    Price / 3-yr avg EPS
    ✗Graham<= 15x
    Price-to-Book Ratio21.6x
    ✗Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value-16.3%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-16.3%, ROC=-808.8%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    Price / Book Value per Share21.6x
    ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Valuation ReasonablenessOE Yield=-4.4%
    ✗MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldFCF Yield=-16.0%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/B=21.6x
    ✗MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Price vs. Trailing Low112% of trailing low ($16.05)
    ✓Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization-12.80%; #4303/6340 (top 67.9%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+0.1067; #4706/6449 (top 73.0%)
    ✗AsnessTop 30% of eligible cross-section
    Price / Diluted EPS
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per Share21.64x
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change-4.0%
    ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+0.0028; #4972/5247 (top 94.8%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization-16.01%; #3427/4519 (top 75.8%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date-47.13%; #5062/6202 (top 81.6%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Cash Flow0% pass✗ 12▾

    All 10 investors flag YARW's cash flow

    Free Cash Flow Proxy$-26.5M
    ✗BuffettPositive and growing
    FCF Positive and Growing$-33.1M
    ✗LynchPositive and growing
    Operating Cash Flow$-33.1M
    ✗PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=-109.83%, ROA=-87.81%
    ✗PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    P/E or FCF YieldFCF Yield=-16.0%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive0/10 years FCF positive
    ✗MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap-5.5%
    ✗Ackman>= 4%
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency0/11 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$-33.1M
    ✗Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization-16.01%; #3427/4519 (top 75.8%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Profitability6% pass✓ 2✗ 33▾

    15 of 16 flag YARW's profitability — Graham, Buffett, Lynch +12 more

    Positive EPS (10 years)2/12 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)0/12 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-85.8%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)-5219.1% (latest)
    ✗BuffettStable or rising over 10 years
    Free Cash Flow Proxy$-26.5M
    ✗BuffettPositive and growing
    Earnings Variance (10-yr CoV)N/A (negative mean EPS)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE-95.4%
    ✗Lynch> 15%
    EBIT / Enterprise Value-16.3%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-16.3%, ROC=-808.8%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets-87.81%
    ✗PiotroskiROA > 0
    ROA Change YoY-59.54% -> -87.81% (delta: -28.27%)
    ✗PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=-109.83%, ROA=-87.81%
    ✗PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY
    ✗PiotroskiImproved YoY
    Pre-Tax Income / Revenue-4689.8%
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity-95.4%
    ✗Dreman> 12%
    Margin of SafetyP/B=21.6x
    ✗PabraiP/B < 1.5 or P/E < 15
    Return on Equity-68.0% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency0/11 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue-5219.1%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity-95.4%
    ✗Ackman>= 15%
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-6900.5% (2023) -> -5219.1% (2025)
    ✓TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendrevenue up, operating margin -6900.5% -> -5219.1%
    ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization-12.80%; #4303/6340 (top 67.9%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets
    ✗AsnessTop 30% of eligible cross-section
    Net income / positive book equity-95.38%; #4574/5226 (top 87.5%)
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.2759; #4534/5884 (top 77.1%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years2/10 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Growth13% pass✓ 4✗ 9▾

    7 of 8 flag YARW's growth — Graham, Lynch, Dreman +4 more

    EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthN/A (no inventory)
    ✓LynchInventory growth < Revenue growth
    EPS Growth Direction$-0.97 (2015) -> $-0.62 (2025)
    ✗DremanPositive over recent years
    EPS CAGR
    ✗Dreman> 5% annualized
    Positive Net Income Frequency0/11 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth13.8%
    ✓Ackman>= 5%
    Positive EPS Growth Frequency3/5 years with positive EPS growth
    ✓AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendrevenue up, operating margin -6900.5% -> -5219.1%
    ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR-51.4%
    ✗SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
  • Verdicts33% pass✓ 5✗ 10▾

    Split decision: 9 FAIL · 5 PASS · 2 NEUTRAL

    Overall verdict
    ✗GrahamFAIL (2/9)✗BuffettFAIL (0/9)✗LynchFAIL (3/7)✗GreenblattRank #2794✓PiotroskiPASS (F-Score 4)✗DremanFAIL (2/11)✓MungerPASS (2/4)✗PabraiFAIL (0/3)✗AkreFAIL (2/6)✗MarksFAIL (0/5)✓AckmanPASS (4/9)✓TempletonPASS (4/8)✓SleepPASS (3/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (0/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)
  • Efficiency38% pass✓ 4✗ 7▾

    5 of 8 flag YARW's efficiency — Buffett, Greenblatt, Munger +2 more

    Current Ratio15.26
    ✓Graham>= 2.0
    ROIC (3-5 yr avg)-2094.5%
    ✗Buffett> 10%
    ROIC - WACC-2104.5%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)-808.8%
    ✗Greenblatt> 25%
    Current Ratio Change YoY4.35 -> 12.53
    ✓PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY0.01x -> 0.02x
    ✓PiotroskiImproved YoY
    Current Assets / Current Liabilities15.26
    ✓Dreman> 1.5
    Return on Invested Capital-84.6%
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=-26.0%; FY2024: ROIC=-66.2%; FY2025: ROIC=-84.6%
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROICN/A (non-positive net income)
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/5 years above 12% (latest -84.6%)
    ✗SleepROIC > 12% in a majority of years

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Pharmaceutical Products
SIC Sector: Chemicals & Pharmaceuticals
Size: Micro Cap($206.9M)
Revenue: $570000.00+13.8% YoY
Net Income: $26.5M+33.5% YoY

Financial Snapshot

Operating Margin-5219.1%
Return on Equity-95.4%
Debt / Equity0.00
Current Ratio12.53
EPS (Diluted)$-0.62
Shares Retired21.8% / −136.4% 2y

Similar Companies

MRKMerck & Co., Inc.
$364.3B
ABTABBOTT LABORATORIES
$188.0B
BMYBRISTOL MYERS SQUIBB CO
$129.7B
TECHBIO-TECHNE Corp
$11.4B

Shareholder Return

Fiscal 2025

Retired 21.8% of shares last year, 136.4% issued over two.

Buybacks
—
Dividends
—

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2025-06-30

2024-07-01 – 2025-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, revenue, net income, operating income, ebit, pre tax income, depreciation amortization.

Q3 FY 2026

2026-07-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization.

Q2 FY 2026

2026-04-01 – 2026-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization.

Q1 FY 2026

2026-01-01 – 2026-03-31

Sources
FY 2025
Sources
  • 10-K · 2026-02-27
FY 2024
Sources
  • 10-K · 2025-03-06
FY 2023
Sources
  • 10-K · 2024-03-01
FY 2022
Sources
  • 10-K · 2024-03-01
FY 2021
Sources
  • 10-K · 2022-03-17
Market Cap$206.9Mcurrent------$18.9Mest.$100.1Mest.$680.4Mest.$431.2Mest.$16.9Best.
Revenue$476.0K--$97.0K↑41%$86.0K↓57%$570.0K↑14%$501.0K↑18%$424.0K↓11%$477.0K↓49%$931.0K
Operating Income-$42.6M-$10.7M-$3.1M↑59%-$3.8M↑59%-$29.7M↑32%-$43.6M↓49%-$29.3M↑15%-$34.3M↑12%-$38.9M
Net Income-$38.5M-$9.7M-$3.0M↑48%-$3.6M↑58%-$26.5M↑34%-$39.8M↓40%-$28.5M↓23%-$23.2M↑68%-$73.3M
EPS (Diluted)--$-0.43$-3.51↓2600%$-0.08↑60%$-0.62↑33%$-0.93↑67%$-2.78↑62%$-7.28↓613%$1.42
Gross Margin————————-259.6%
Operating Margin-8949.6%—-3197.9%↑71%-4437.2%↑3%-5219.1%↑40%-8710.0%↓26%-6900.5%↑4%-7189.7%↓72%-4179.5%
ROE-99.1%———-95.4%↓25%-76.5%↓139%-32.1%↑57%-74.4%↑51%-150.8%
Total Debt$0$0$0$0$0$0$0$0$0
Shareholders' Equity$38.9M$267.5M$22.1M↓43%$24.6M↓44%$27.8M↓47%$52.1M↓41%$88.7M↑184%$31.2M↓36%$48.6M
Current Ratio7.6042.0815.26↑101%20.86↑367%12.53↑188%4.35↓66%12.73↑211%4.10↑19%3.43
Debt / Equity0.000.000.000.000.000.000.000.000.00
Operating Cash Flow-$39.8M-$90.0M-$2.0M↑82%-$4.1M↑64%-$33.1M↑2%-$34.0M↓34%-$25.3M↑13%-$29.2M↑48%-$56.4M
Free Cash Flow---------$33.1M↑3%-$34.1M↓35%-$25.3M---$56.4M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Pharmaceutical Products

YARW vs Peers — Financial Grading

Revenue$570000.00Bottom 25%
Net Income$26.5MBottom 25%
ROE-95.4%Bottom 25%
D/E0.00Top 25%
Op. Margin-5219.1%Bottom 25%
Curr. Ratio12.53Top 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11